- Title
- A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Creators
- Aaron D Goldberg - Memorial Sloan Kettering Cancer CenterMaro Ohanian - The University of Texas MD Anderson Cancer CenterPaul B. Koller - City Of Hope National Medical CenterMohamad Cherry - Morristown Medical CenterJessica K. Altman - Northwestern UniversityBenjamin Tomlinson - University Hospitals of ClevelandNamrata Sonia Chandhok - University of MiamiDonna Nguyen HaneyJia Hu - Aptose BiosciencesRanjeet Kumar Sinha - Aptose BiosciencesWilliam G Rice - Aptose BiosciencesRafael Bejar - University of California, San Diego
- Publication Details
- Blood, Vol.140(Supplement 1), pp.6220-6221
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031786582702976
Journal article
A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Blood, Vol.140(Supplement 1), pp.6220-6221
2022-11-15
Metrics
1 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.103 Blood Disorders
- 1.103.155 Acute Myeloid Leukemia
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites